X4 PHARMACEUTICALS, INC Depreciation
X4 PHARMACEUTICALS, INC (XFOR) reported Depreciation of $71.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC depreciation for the quarter ending 2026-06-30 was $35.00K, a 79.17% decline year-over-year.
- X4 PHARMACEUTICALS, INC depreciation for the quarter ending 2026-03-31 was $36.00K, a 87.54% decline year-over-year.
- X4 PHARMACEUTICALS, INC depreciation for the quarter ending 2025-06-30 was $168.00K, a 143.48% increase year-over-year.
- X4 PHARMACEUTICALS, INC depreciation for the quarter ending 2025-03-31 was $289.00K, a 366.13% increase year-over-year.
- X4 PHARMACEUTICALS, INC depreciation for fiscal 2025 was $500.00K, a 66.67% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC depreciation for fiscal 2024 was $300.00K, a 25.00% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC depreciation for fiscal 2023 was $400.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $71.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $36.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $500.00K 10-K · filed 2026-03-17 | |||
| 2025-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $457.00K 10-Q · filed 2026-08-06 | $546.00K derived: sum of 3 quarters · filed 2026-08-06 | $626.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $289.00K 10-Q · filed 2026-05-06 | $378.00K derived: sum of 2 quarters · filed 2026-05-06 | $458.00K derived: sum of 3 quarters · filed 2026-05-06 | $527.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $169.00K derived: sum of 2 quarters · filed 2026-03-17 | $238.00K derived: sum of 3 quarters · filed 2026-03-17 | $300.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $149.00K derived: sum of 2 quarters · filed 2025-08-08 | $211.00K 10-Q · filed 2024-11-13 | $254.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $131.00K 10-Q · filed 2025-08-08 | $174.00K derived: sum of 3 quarters · filed 2026-03-17 | $278.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $62.00K 10-Q · filed 2025-05-01 | $105.00K derived: sum of 2 quarters · filed 2026-03-17 | $209.00K derived: sum of 3 quarters · filed 2026-03-17 | |
| 2023-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $147.00K derived: sum of 2 quarters · filed 2026-03-17 | $400.00K 10-K · filed 2026-03-17 | |
| 2023-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $357.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $253.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |